1256955-27-7

Basic information

• Product Name: 6-broMo-4-chloro-7-Methoxyquinazoline
• Synonyms: 6-bromo-4-chloro-7-mcthoxyquinazoline
• CAS NO: 1256955-27-7
• Molecular Formula: C₉H₆BrClN₂O
• Molecular Weight: 273.51374
• Mol File: 1256955-27-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.686±0.06 g/cm3 (20 oC 760 Torr)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 6-broMo-4-chloro-7-Methoxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-broMo-4-chloro-7-Methoxyquinazoline(1256955-27-7)
• EPA Substance Registry System: 6-broMo-4-chloro-7-Methoxyquinazoline(1256955-27-7)

Safety Data

• Hazardous Substances Data: 1256955-27-7(Hazardous Substances Data)

Usage

General Description

6-bromo-4-chloro-7-methoxyquinazoline is a chemical compound with a unique structure that contains a quinazoline ring with bromine, chlorine, and methoxy substituents. It is commonly used in organic synthesis and medicinal chemistry research as a building block for the synthesis of pharmaceutical compounds. 6-bromo-4-chloro-7-methoxyquinazoline has potential for use in the development of new drugs due to its diverse biological activities, including antitumor and anticancer properties. Additionally, 6-bromo-4-chloro-7-methoxyquinazoline has been studied for its antimalarial and antibacterial properties, making it an important target for further investigation in drug discovery and development.

Upstream product

• 950577-02-3 6-bromo-7-fluoroquinazolin-4-ol 
• 169045-04-9 2-amino-5-bromo-4-methoxybenzoic acid 
• 4294-95-5 4-methoxyanthranilic acid 
• 169044-96-6 methyl 2-amino-5-bromo-4-methoxybenzoate 
• 950577-05-6 6-bromo-7-methoxyquinazoline-4(3H)-one 

Relevant articles and documents

BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR and erbB2 activity, as well as methods for using such compounds to treat cancer associated with mutant EGFR and erbB2 activity.

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed 10 Compound's of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.